Caribou nets $115M to boost CRISPR tech, advance off-the-shelf cell therapies
Caribou nets $115M to boost CRISPR tech, advance off-the-shelf cell therapies On the heels of a new partnership with AbbVie, Caribou Biosciences is reeling in $115 million to keep improving its CRISPR technology and shepherd its pipeline of allogeneic, or off-the-shelf, cell therapies into and through the clinic. Caribou’s most advanced program is CB-101, an […]
Read More